Should I buy or sell Viridian Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares. View VRDN analyst ratings or view top-rated stocks .

What is Viridian Therapeutics' stock price target for 2024?

10 Wall Street research analysts have issued 1-year target prices for Viridian Therapeutics' shares. Their VRDN share price targets range from $25.00 to $46.00. On average, they predict the company's share price to reach $36.60 in the next twelve months. This suggests a possible upside of 151.5% from the stock's current price. View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts .

How have VRDN shares performed in 2024?

Viridian Therapeutics' stock was trading at $21.78 at the beginning of 2024. Since then, VRDN stock has decreased by 33.2% and is now trading at $14.55. View the best growth stocks for 2024 here .

Are investors shorting Viridian Therapeutics?

Viridian Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,470,000 shares, an increase of 24.3% from the March 15th total of 7,620,000 shares. Based on an average trading volume of 962,900 shares, the days-to-cover ratio is presently 9.8 days. View Viridian Therapeutics' Short Interest .

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VRDN earnings forecast .

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.37. The firm earned $0.07 million during the quarter, compared to analysts' expectations of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. Viridian Therapeutics's revenue was down 31.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.13) EPS.

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.17%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin , Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers. View institutional ownership trends .

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:VRDN

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VRDN Stock Alerts

$14.60

-0.56 (-3.69%)

(As of 04/19/2024 ET)

Compare

Today's Range: $14.40
▼
$15.51
50-Day Range: $15.08
▼
$20.17
52-Week Range: $10.93
▼
$30.30

Volume: 1.49 million shs
Average Volume: 937,983 shs
Market Capitalization: $916.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.60

Get Viridian Therapeutics alerts:

Viridian Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 151.5% Upside
$36.60 Price Target
Short Interest: Bearish
15.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.23
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($4.39) to ($4.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

Medical Sector

720th out of 918 stocks

Medical Laboratories Industry

17th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Viridian Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Viridian Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.09% of the outstanding shares of Viridian Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Viridian Therapeutics has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in Viridian Therapeutics has recently increased by 24.28%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Viridian Therapeutics does not currently pay a dividend.
Dividend Growth
Viridian Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VRDN.

2.9

News and Social Media Coverage

News Sentiment
Viridian Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Viridian Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 12 people have searched for VRDN on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.
MarketBeat Follows
11 people have added Viridian Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 57% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viridian Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,999,990.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.43% of the stock of Viridian Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Viridian Therapeutics are expected to grow in the coming year, from ($4.39) to ($4.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viridian Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viridian Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viridian Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

VRDN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRDN Stock News Headlines

April 13, 2024 | fool.com

Viridian Therapeutics (NASDAQ: VRDN)

April 13, 2024 | americanbankingnews.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Increase in Short Interest

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market Potential

April 4, 2024 | businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024 | prnewswire.com

VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

March 25, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), OmniAb (OABI) and Vericel (VCEL)

March 20, 2024 | markets.businessinsider.com

Buy Rating Endorsed for Viridian Therapeutics’ VRDN Treatments Based on Superior Efficacy and Dosing Advantages in TED Market

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 20, 2024 | markets.businessinsider.com

Unveiling 4 Analyst Insights On Viridian Therapeutics

March 19, 2024 | investorplace.com

Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20

March 16, 2024 | finance.yahoo.com

VRDN Sep 2024 20.000 put

March 16, 2024 | finance.yahoo.com

VRDN Apr 2024 20.000 put

March 15, 2024 | stockhouse.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm

March 9, 2024 | nasdaq.com

VRDN Makes Bullish Cross Above Critical Moving Average

March 6, 2024 | businesswire.com

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 5, 2024 | finance.yahoo.com

Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Viridian Therapeutics Amid Strong Clinical Progress and Market Potential

February 29, 2024 | markets.businessinsider.com

Buy Rating on Viridian Therapeutics Backed by Pipeline Progress and Phase 3 Trial Potential

February 29, 2024 | finance.yahoo.com

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Viridian Therapeutics Amid Strong Drug Pipeline Progress and Robust Financial Position

February 28, 2024 | msn.com

Viridian Therapeutics GAAP EPS of -$1.35

February 27, 2024 | businesswire.com

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

February 22, 2024 | markets.businessinsider.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Viridian Therapeutics, Inc. (VRDN)

February 17, 2024 | finance.yahoo.com

VRDN Mar 2024 30.000 put

February 16, 2024 | finance.yahoo.com

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

February 16, 2024 | businesswire.com

Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer

See More Headlines

Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:VRDN
CUSIP: N/A
CIK: 1590750
Web: www.viridiantherapeutics.com
Phone: (617) 272-4600
Fax: 760-537-4101
Employees: 94
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.60
High Stock Price Target: $46.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +139.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-237,730,000.00
Net Margins: -75,711.48%
Pretax Margin: -75,711.46%
Return on Equity: -121.80%
Return on Assets: -61.06%

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 18.26
Quick Ratio: 18.26

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 3,095.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.48 per share
Price / Book: 3.41

Miscellaneous

Outstanding Shares: 62,770,000
Free Float: 61,870,000
Market Cap: $959.75 million
Optionable: Optionable
Beta: 1.07

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Stephen F. Mahoney J.D. (Age 52)
MBA, CEO, President & Director
Dr. Eric N. Olson Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael R. Bristow M.D. (Age 79)
Ph.D., Co-Founder & Member of the Scientific Advisory Board
Dr. Marvin H. Caruthers Ph.D. (Age 84)
Co-Founder & Scientific Advisory Board Member
Mr. Vahe Bedian Ph.D.
Co-Founder & Scientific Advisor
Mr. Seth Harmon
Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
Mr. Thomas W. Beetham J.D. (Age 54)
MBA, Chief Operating Officer
Ms. Jennifer Tousignant J.D.
Chief Legal Officer
Mr. John A. Jordan
Vice President of Investor Relations & Corporate Communications
Mr. Anthony Casicano (Age 47)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VRDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings or view top-rated stocks.
What is Viridian Therapeutics' stock price target for 2024?: 10 Wall Street research analysts have issued 1-year target prices for Viridian Therapeutics' shares. Their VRDN share price targets range from $25.00 to $46.00. On average, they predict the company's share price to reach $36.60 in the next twelve months. This suggests a possible upside of 151.5% from the stock's current price.
View analysts price targets for VRDN or view top-rated stocks among Wall Street analysts.
How have VRDN shares performed in 2024?: Viridian Therapeutics' stock was trading at $21.78 at the beginning of 2024. Since then, VRDN stock has decreased by 33.2% and is now trading at $14.55.
View the best growth stocks for 2024 here.
Are investors shorting Viridian Therapeutics?: Viridian Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,470,000 shares, an increase of 24.3% from the March 15th total of 7,620,000 shares. Based on an average trading volume of 962,900 shares, the days-to-cover ratio is presently 9.8 days.
View Viridian Therapeutics' Short Interest.

When is Viridian Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRDN earnings forecast.
How were Viridian Therapeutics' earnings last quarter?: Viridian Therapeutics, Inc. (NASDAQ:VRDN) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.37. The firm earned $0.07 million during the quarter, compared to analysts' expectations of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. Viridian Therapeutics's revenue was down 31.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.13) EPS.
Who are Viridian Therapeutics' major shareholders?: Viridian Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.17%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers.
View institutional ownership trends.
How do I buy shares of Viridian Therapeutics?: Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRDN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial